Integer Holdings (NYSE:ITGR) posted third-quarter results today that beat the consensus forecast on Wall Street — and announced plans to spend $220 million to acquire Oscor. The Plano, Texas–based medtech contract manufacturing giant plans to finance the acquisition with debt. Integer officials expect the deal to close in December under customary closing conditions. They see […]
Micro Interventional Devices said today that contract manufacturer Oscor led its $20 million Series D round and inked an OEM deal. Newtown, Pa.-based MID said the deal involves a non-exclusive license for Palm Harbor, Fla.-based Oscor’s catheter technology, in return for Oscor’s exclusive right to its MID’s Mia device for treating tricuspid and mitral valve […]
Oscor is voluntarily recalling a select number of TB temporary bipolar pacing leads with 2mm unshrouded connectors over issues which may expose the connection wire, according to a recently posted FDA alert. The company said that the connector cap housing on the leads may cause the wire to be more susceptible to loss of connectivity […]
Sometimes working for your dad seems like destiny, but taking over the family business wasn’t always the plan. There are many second- and third-generation medtech manufacturers run by executives following in their dads’ footsteps. Here’s what they learned. Eric Crainich, president and owner of Design Standards (Charlestown, N.H.), was told from a young age that […]
The FDA last month warned contract manufacturer Oscor on its methods for documenting process controls for the catheters and neurostimulation leads it makes, after inspections in February and March turned up a trio of violations. The federal safety watchdog said it inspected Oscor’s plant in Palm Harbor, Fla., where it makes the Adelante Magnum introducer catheter and lead […]
Group purchasing organization Premier Healthcare Alliance struck a deal with 4 major players in the cardiac device market for several cardiac rhythm management device portfolios.
Group purchasing organization Novation awarded new cardiovascular contracts to a host of market leaders, effective at the beginning of 2013.